SCHEMBL3703112

SCHEMBL3703112

O=[S@]1OC[C@H](c2ccc(OCCCOC3CCN(c4ncccn4)CC3)cc2)CO1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.39
DRD3 P35462 2/20 0.39
HTR1A P08908 1/20 0.39
DRD1 P21728 1/20 0.39
HTR2A P28223 1/20 0.39
HRH3 Q9Y5N1 8/20 0.39
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
USP2 O75604 1/20 0.36
ALOX15 P16050 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
SLC6A7 Q99884 2/20 0.35
TSHR P16473 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3700389 1.00 DRD2 (0.39) DRD2DRD3HTR1ADRD1HTR2A
SCHEMBL3700392 1.00 DRD2 (0.39) DRD2DRD3HTR1ADRD1HTR2A
SCHEMBL2716581 0.83 ADRA1D (0.36) KDM4EALDH1A1
SCHEMBL2729792 0.80 DRD2 (0.38) DRD2DRD3HTR1ADRD1HTR2A
SCHEMBL2718576 0.76 S1PR1 (0.36) HRH3MEN1KMT2AALDH1A1CYP3A4
SCHEMBL2718956 0.75 GPR119 (0.48) MEN1KMT2AKDM4EALDH1A1CYP3A4
SCHEMBL2729403 0.75 GPR119 (0.48) MEN1KMT2AKDM4EALDH1A1CYP3A4
SCHEMBL3702657 0.75 GPR119 (0.48) MEN1KMT2AKDM4EALDH1A1CYP3A4
SCHEMBL2730168 0.75 GPR119 (0.41)
SCHEMBL3699548 0.75 GPR119 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8772302-B2 GPR 119 agonists CADILA HEALTHCARE LIMITED (IN) 2014-07-08 US claimed
EP-2445904-B1 1,3,2-DIOXATHIANE-2-OXIDE DERIVATIVES AND THEIR USE AS GPR 119 AGONISTS CADILA HEALTHCARE LTD (IN) 2013-09-11 EP claimed
US-20120122905-A1 NOVEL GPR 119 AGONISTS CADILA HEALTHCARE LIMITED (IN) 2012-05-17 US claimed
US-8772302-B2 GPR 119 agonists CADILA HEALTHCARE LIMITED (IN) 2014-07-08 US disclosed
EP-2445904-B1 1,3,2-DIOXATHIANE-2-OXIDE DERIVATIVES AND THEIR USE AS GPR 119 AGONISTS CADILA HEALTHCARE LTD (IN) 2013-09-11 EP disclosed
US-20120122905-A1 NOVEL GPR 119 AGONISTS CADILA HEALTHCARE LIMITED (IN) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122905-A1 NOVEL GPR 119 AGONISTS GPR119, GPR4, GPR39 DRD2 491/4885DRD3 793/4885HTR1A 225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.